[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

United States Active Pharmaceutical Ingredient Market, By Method of Synthesis (Biological v/s. Synthetic), By Source (In-house v/s Contract Manufacturing Organizations), By Distribution Channel (Online v/s Offline), By Therapeutic Application (Cardiovascular Disease, Anti-diabetic, Oncology, Neurological Disorders, Musculoskeletal, Others), By Form (Tablet, Capsule, Injection, Others), By Molecule Type (Small v/s Large), By Potency (High v/s Low), By Drug Type (Innovator v/s Generic), By Region, Competition Forecast & Opportunities, 2016 – 2026

February 2021 | 71 pages | ID: U4AAC0E07FCEEN
TechSci Research

US$ 4,400.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
United States active pharmaceutical ingredient market stood at USD17.81 billion in 2020 and is projected to grow at a CAGR of 9.73% to cross USD31.48 billion by 2026. This can be attributed to growing prevalence of chronic diseases such as cardiovascular diseases, diabetes, cancer, respiratory disorders, among others. This has drastically increased the patient pool thereby increasing the demand for drugs. This in turn is expected to positively influence the market growth through 2026. Additionally, increasing R&D by various biopharmaceutical companies in drug discovery is further expected to spur the market growth over the next few years. Besides this, growing importance of generics is also expected to foster the market growth in the next five years.

United States active pharmaceutical ingredient market can be segregated based on method of synthesis, source, distribution channel, therapeutic application, form, molecule type, potency, drug type, region and company. Based on method of synthesis, the market can be split into synthetic and biological. The synthetic method of synthesis dominated the market with a share of 58.29% in 2020 on account of the easy availability of raw materials and easier process for development of active pharmaceutical ingredients. While the biological method of synthesis segment is expected to grow at a rate of 10.82% during the forecast period owing to the growing demand for vaccines, monoclonal antibodies, recombinant proteins, biosimilars, among others.

Leading players operating in the market include Teva Pharmaceutical Industries Limited, Merck & Co., Inc., Pfizer Inc., Dr. Reddy’s Laboratories Limited, Lupin Pharmaceuticals, Inc., Glenmark Pharmaceuticals, Inc., GlaxoSmithKline Plc, Novartis Inc. (Sandoz), Aurobindo Pharma USA, Inc., Sun Pharmaceutical Industries Ltd., Eli Lilly and Company, AbbVie Inc., Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd., Sanofi-Aventis U.S. LLC and others. Major companies are developing advanced technologies and launching new products to stay competitive in the market. Other competitive strategies include mergers & acquisitions and new product developments. For instance, in 2020, Pfizer (US) signed a multiyear agreement with Gilead Sciences Inc., to manufacture and supply Gilead’s antiviral drug (Remdesivir) for the treatment of COVID-19.

Years Considered for this Report:
  • Historical Years: 2016 – 2019
  • Base Year: 2020
  • Estimated Year: 2021
  • Forecast Period: 2022– 2026
Objective of the Study:
  • The primary objective of the study was to evaluate and forecast active pharmaceutical ingredient market in United States from 2021-2026.
  • To categorize the market on the basis of method of synthesis, source, distribution channel, therapeutic application, form, molecule type, potency, drug type, region and company.
  • To identify major drivers, challenges and trends in the United States active pharmaceutical ingredient market.
  • To identify the dominant region or segment in the United States active pharmaceutical ingredient market.
  • To examine competitive developments such as expansions, new product launches, mergers and acquisitions, etc., in the United States active pharmaceutical ingredient market.
  • To identify and analyze the profiles of leading players operating in the United States active pharmaceutical ingredient.
  • To identify key sustainable strategies adopted by market players in the United States active pharmaceutical ingredient market.
To extract the data for United States active pharmaceutical ingredient market, primary research surveys were conducted with API manufacturer and contract manufacturer companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research was able to include manufacturers that could not be identified due to the limitations of secondary research. Moreover, TechSci Research analyzed various end user segments and projected a positive outlook for United States active pharmaceutical ingredient market over the coming years.

TechSci Research calculated the market size of United States active pharmaceutical ingredient market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated them by analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience:
  • Active pharmaceutical ingredient manufacturers, contract manufacturers and other stakeholders
  • Market research and consulting firms
  • Government bodies such as regulating authorities and policy makers
  • Organizations, forums and alliances related to active pharmaceutical ingredient
The study is useful in providing answers to several critical questions that are important for industry stakeholders, such as active pharmaceutical ingredient manufacturers, customers and policymakers. The report also provides useful insights about which market segments should be targeted over the coming years to strategize investments and capitalize on growth opportunities.

Report Scope:

In this report, United States active pharmaceutical ingredient market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
  • Market, By Method of Synthesis:
    • Synthetic
    • Biological
  • Market, By Source:
    • Contract Manufacturing Organizations
    • In-house manufacturing
  • Market, By Distribution Channel:
    • Offline
    • Online
  • Market, By Therapeutic Application:
    • Cardiovascular Disease
    • Anti-diabetic
    • Oncology
    • Neurological Disorders
    • Musculoskeletal
    • Others
  • Market, By Form:
    • Tablets
    • Capsule
    • Injection
    • Others
  • Market, By Molecule Type:
    • Small
    • Large
  • Market, By Potency:
    • Low
    • High
  • Market, By Drug Type:
    • Innovator
    • Generics
  • Market, By Region:
    • North-East
    • Mid-West
    • West
    • South
Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the United states active pharmaceutical ingredient market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information
  • Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW

2. RESEARCH METHODOLOGY

3. IMPACT OF COVID-19 ON UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENT MARKET

4. EXECUTIVE SUMMARY

5. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT MARKET OUTLOOK

6. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENT MARKET OUTLOOK

6.1. Market Size & Forecast
  6.1.1. By Value
6.2. Market Share & Forecast
  6.2.1. By Method of Synthesis (Biological v/s. Synthetic)
  6.2.2. By Source (In-house v/s Contract Manufacturing Organizations)
  6.2.3. By Distribution Channel (Online v/s Offline)
  6.2.4. By Therapeutic Application (Cardiovascular Disease, Anti-diabetic, Oncology, Neurological Disorders, Musculoskeletal, Others)
  6.2.5. By Form (Tablet, Capsule, Injection, Others)
  6.2.6. By Molecule Type (Small v/s Large)
  6.2.7. By Potency (High v/s Low)
  6.2.8. By Drug Type (Innovator v/s Generic)
  6.2.9. By Region (West, Mid-West, North-East, South)
  6.2.10. By Company
6.3. Product Market Map

7. UNITED STATES BIOLOGICAL ACTIVE PHARMACEUTICAL INGREDIENT MARKET OUTLOOK

7.1. Market Size & Forecast
  7.1.1. By Value
7.2. Market Share & Forecast
  7.2.1. By Product Type (Recombinant Proteins, Vaccines, Monoclonal Antibodies, Hormones, Others)
  7.2.2. By Therapeutic Application
  7.2.3. By Source
  7.2.4. By Distribution Channel
  7.2.5. By Form
  7.2.6. By Molecule Type
  7.2.7. By Potency
  7.2.8. By Drug Type

8. UNITED STATES SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENT MARKET OUTLOOK

8.1. Market Size & Forecast
  8.1.1. By Value
8.2. Market Share & Forecast
  8.2.1. By Product Type (Inorganic Synthetic Drugs vs. Organic Synthetic Drugs)
  8.2.2. By Therapeutic Application
  8.2.3. By Source
  8.2.4. By Distribution Channel
  8.2.5. By Form
  8.2.6. By Molecule Type
  8.2.7. By Potency
  8.2.8. By Drug Type

9. MARKET DYNAMICS

9.1. Drivers
9.2. Challenges

10. MARKET TRENDS & DEVELOPMENTS

11. TRADE DYNAMICS (TOP 5 APIS)

11.1. Export
11.2. Import

12. POLICY & REGULATORY LANDSCAPE

13. UNITED STATES ECONOMIC PROFILE

14. COMPETITIVE LANDSCAPE (SWOT ANALYSIS OF TOP 5 PLAYERS)

14.1. Competition Outlook
14.2. Company Profiles
  14.2.1. Teva Pharmaceutical Industries Limited
  14.2.2. Merck & Co., Inc.
  14.2.3. Pfizer Inc.
  14.2.4. Dr. Reddy’s Laboratories Limited
  14.2.5. Lupin Pharmaceuticals, Inc.
  14.2.6. Glenmark Pharmaceuticals, Inc.
  14.2.7. GlaxoSmithKline Plc
  14.2.8. Novartis Inc. (Sandoz)
  14.2.9. Aurobindo Pharma USA, Inc.
  14.2.10. Sun Pharmaceutical Industries Ltd.
  14.2.11. Eli Lilly and Company
  14.2.12. AbbVie Inc.
  14.2.13. Bristol-Myers Squibb
  14.2.14. F. Hoffmann-La Roche Ltd.
  14.2.15. Sanofi-Aventis U.S. LLC

15. STRATEGIC RECOMMENDATIONS

16. ABOUT US & DISCLAIMER

LIST OF FIGURES

Figure 1: Global Active Pharmaceutical Ingredient Market Size, By Value (USD Billion), 2016-2026
Figure 2: United States Active Pharmaceutical Ingredient Market Size, By Value (USD Billion), 2016-2026
Figure 3: United States Active Pharmaceutical Ingredient Market Share, By Method of Synthesis, By Value, 2016-2026
Figure 4: United States Active Pharmaceutical Ingredient Market Share, By Source, By Value, 2016-2026
Figure 5: United States Active Pharmaceutical Ingredient Market Share, By Distribution Channel, By Value, 2016-2026
Figure 6: United States Active Pharmaceutical Ingredient Market Share, By Therapeutic Application, By Value, 2016-2026
Figure 7: United States Active Pharmaceutical Ingredient Market Share, By Form, By Value, 2016-2026
Figure 8: United States Active Pharmaceutical Ingredient Market Share, By Molecule Type, By Value, 2016-2026
Figure 9: United States Active Pharmaceutical Ingredient Market Share, By Potency, By Value, 2016-2026
Figure 10: United States Active Pharmaceutical Ingredient Market Share, By Drug Type, By Value, 2016-2026
Figure 11: United States Active Pharmaceutical Ingredient Market Share, By Region, By Value, 2016-2026
Figure 12: United States Active Pharmaceutical Ingredient Market Share, By Company, By Value, 2016-2026
Figure 13: United States Biological Active Pharmaceutical Ingredient Market Size, By Value (USD Billion), 2016-2026
Figure 14: United States Biological Active Pharmaceutical Ingredient Market Share, By Method of Synthesis, By Value, 2016-2026
Figure 15: United States Biological Active Pharmaceutical Ingredient Market Share, By Source, By Value, 2016-2026
Figure 16: United States Biological Active Pharmaceutical Ingredient Market Share, By Distribution Channel, By Value, 2016-2026
Figure 17: United States Biological Active Pharmaceutical Ingredient Market Share, By Therapeutic Application, By Value, 2016-2026
Figure 18: United States Biological Active Pharmaceutical Ingredient Market Share, By Form, By Value, 2016-2026
Figure 19: United States Biological Active Pharmaceutical Ingredient Market Share, By Molecule Type, By Value, 2016-2026
Figure 20: United States Biological Active Pharmaceutical Ingredient Market Share, By Potency, By Value, 2016-2026
Figure 21: United States Biological Active Pharmaceutical Ingredient Market Share, By Drug Type, By Value, 2016-2026
Figure 22: United States Synthetic Active Pharmaceutical Ingredient Market Size, By Value (USD Billion), 2016-2026
Figure 23: United States Synthetic Active Pharmaceutical Ingredient Market Share, By Method of Synthesis, By Value, 2016-2026
Figure 24: United States Synthetic Active Pharmaceutical Ingredient Market Share, By Source, By Value, 2016-2026
Figure 25: United States Synthetic Active Pharmaceutical Ingredient Market Share, By Distribution Channel, By Value, 2016-2026
Figure 26: United States Synthetic Active Pharmaceutical Ingredient Market Share, By Therapeutic Application, By Value, 2016-2026
Figure 27: United States Synthetic Active Pharmaceutical Ingredient Market Share, By Form, By Value, 2016-2026
Figure 28: United States Synthetic Active Pharmaceutical Ingredient Market Share, By Molecule Type, By Value, 2016-2026
Figure 29: United States Synthetic Active Pharmaceutical Ingredient Market Share, By Potency, By Value, 2016-2026
Figure 30: United States Synthetic Active Pharmaceutical Ingredient Market Share, By Drug Type, By Value, 2016-2026


More Publications